drugset / Trial / NCT06241573

A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

NCT06241573 ↗

Phase 2/3 Terminated 39 enrolled Boehringer Ingelheim
Non-randomizedParallel-groupQuadruple-blindTreatment

Summary

This study is open to people with hidradenitis suppurativa (HS) who have completed another study with spesolimab (study 1368-0098 (NCT05819398) or study 1368-0100). The purpose of this study is to find out how well people tolerate spesolimab and whether it helps people with HS in the long-term. For about 1.5 years, participants get spesolimab injections under the skin every 2 weeks. Participants are in the study for about 2 years. During this time, participants have 41 visits. 24 visits are done at the study site. 17 visits can be done by video call at the participant's home. At study visits, doctors check the severity of the participant's HS and collect information on any health problems of the participants.

Timeline

Start
2024-05-08
Primary completion
2025-04-11
Completion
2025-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Spesolimab Monoclonal antibody — Subcutaneous